DDInter1076 DDInter364
A vitamin-like antioxidant.
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} (Compound) resembles {v} (Compound) Aminocaproic acid
Aminocaproic acid {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) interacts with {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Lipoic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid {u} (Compound) binds {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) is downregulated by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Lipoic acid (Compound) resembles Aminocaproic acid (Compound) and Aminocaproic acid (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid (Compound) resembles Chlorpropamide (Compound)
Lipoic acid (Compound) binds POR (Gene) and POR (Gene) interacts with CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Chlorpropamide (Compound)
Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid (Compound) resembles Chlorpropamide (Compound)
Lipoic acid (Compound) binds SLC5A6 (Gene) and SLC5A6 (Gene) is downregulated by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)